Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Finally, a Stem Cell Trial for Ischemic Stroke; ReNeuron (RENE.L) 1 comment
    Feb 11, 2010 7:22 AM

    ReNeuron has been … finally … given full regulatory approval by the UK Gene Therapy Advisory Committee to initiate a stem cell trial for ischemic stroke after a 5 years approval cycle.

    RENE.L also has new preclinical data backing the efficacy of its lead CTX stem cell line for peripheral arterial disease.

    • The stem cells have generated “significant recovery of blood flow” in the ischemic limb. This CTX cell line has been extremely well-characterized and scaled up and extensively tested as part of their ReN001 program.  Hopefully, this cell line will be able to further the clinic trial as a non-patient-specific therapeutic candidate for peripheral arterial disease,
    • In this Glasgow based trial, 12 stroke victims in groups of 3 groups and treated with fetal stem cells for 6 to 24 months following a stroke,
    • Doses will begin at around 2 M brain cells and grow to 20 M,
    • The stem cells being tested have been extracted from the fetuses of aborted babies has sparked controversy in the UK,
    • Repeated attempts to get the US FDA to approve a Phase I trial have dragged on for many months (almost a year) with the US FDA still seeking more information on their ReN001 candidate.

    “If it (stem cell therapy) works, as it has done in animal model systems, it (this therapy) may allow new nerve cells to grow or regeneration existing cells with actual recovery of function in patients who would not otherwise be able to regain function.”  (BBC News)

    ReNeuron is a UK-based stem cell company. Their primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. RENE.L’s shares are traded on the London AIM market.

    • Reiterating, RENE.L should be watched for future news and platform development within this sector/ industry,
    • RENE.L since our last post on 1/29/09 ,  is trading down at £7.05  (52 week range of £3.50 to £11.35) with a market cap of £23.17  M.
Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • lamanga2004
    , contributor
    Comment (1) | Send Message
    The original stem cells were extracted from one foetus. Just one. Their entire cell line has been grown from those few initial cells.
    11 Feb 2010, 07:44 AM Reply Like
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.